Philochem and Bracco Imaging collaborate on the development of a molecule for diagnostic applications

Siena-Milan, Italy , 03/22/2022

Philochem, a subsidiary of the Philogen Group, and Bracco Imaging today announce that they have entered into a license and collaboration agreement to develop and commercialize a small organic molecule for imaging applications, with proven ability to selectively detect a variety of metastatic solid tumors in cancer patients, paving the way for a new approach to tumor diagnosis.